ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS

SANTINI, VALERIA; BEJAR, RAFAEL; BELLI, CAROLINA; BUCKSTEIN, RENA; DIAZ CAMPELO, MARIA; DEZERN, AMY; FONTANAY, MICHAËLA; GRIFFITHS, ELIZABETH; GRILLÉ, SOFÍA; HAFERLACH, TORSTEN; IASTREBNER, MARCELO; KOSMIDER, OLIVER; MAGALHÃES, SÍLVIA MARIA MEIRA; MITTELMAN, MOSHE; PLATZBECKER, UWE; WEI, ANDREW; ZEIDAN, AMER

Marseille

Congreso; 17th International Congress of Myelodysplastic Syndromes; 2023

MDS Foundation

Background And Aims: The use of NGS has not yet become a widespreadroutine diagnostic analysis for MDS, despite IPSS-M relevance and inclusionof germline predisposition analysis in WHO and ICC classifications.Methods: We performed a real world survey to clarify the proportion ofMDS patients for whom NGS evaluation of somatic mutations was availableand possible, for which specific genes, as well as the reimbursement policyand legislations in different Countries: Australia, Canada, EU, Israel, LatinAmerica, US.Results: Availability of NGS is highly heterogeneous, as well as reimbursementpolicy, ranging from full reimbursement by health systems orinsurances (mainly for some European Countries and US), to completeabsence. Still only a limited proportion of MDS patients receive molecularevaluation, especially in smaller hospital and community centers. In someinstances, complex reimbursement systems prevent application of NGS foroutpatients. Generally, the number of genes whose evaluation is reimbursedis limited and variable. Academic centers offer NGS ranging from 90to 50% of cases, compared to 40-